This guidance, originally published in 2003, contains the following introduction:
Regulatory Policy, Analysis, & Guidance
Reports
Displaying 1 - 10 of 67. 10 per page. Page 1.
Advanced SearchASPE Data Point
HHS Standard Values for Regulatory Analysis
The U.S. Department of Health and Human Services (HHS) analyzes the benefits, costs, and other impacts of significant proposed and final rulemakings, consistent with the requirements of several executive orders and statutes. HHS develops these analyses according to technical guidance published by the U.S.
Report
Updated Medicare FFS Telehealth Trends by Beneficiary Characteristics, Visit Specialty and State, 2019-2021
This research report updates prior reports on Medicare FFS telehealth trends during the COVID-19 public health emergency with data through end of 2021, by beneficiary characteristics, visit specialty and geography including by state. Medicare telehealth flexibilities during the COVID-19 pandemic continued to encourage use of telehealth among Medicare beneficiaries in 2021.
ASPE Issue Brief
FDA User Fees: Examining Changes in Medical Product Development and Economic Benefits
This issue brief provides a primer on FDA user fees, presents findings of how user fees affect the cost of medical product development, and summarizes the research literature on user fees, most notably in expediting medical product development and approval.
Report
Addressing Uncertainty in Regulatory Impact Analysis
In 2016, the U.S. Department of Health and Human Services finalized its Guidelines for Regulatory Impact Analysis under the leadership of its Assistant Secretary for Planning Evaluation and Analytics Team. The Guidelines discuss strategies for characterizing the uncertainty in quantified effects as well as the potential impacts of non-quantified effects.
Report
Guidelines for Regulatory Impact Analysis Supplement: Addressing International Effects
This report extends the brief discussion of addressing international effects contained in the Department of Health and Human Service Guidelines for Regulatory Impact Analysis (2016). The purpose of this supplement is to expand that discussion and provide more detailed information on conducting such assessments.
Related Products:
Report
Valuing COVID-19 Mortality and Morbidity Risk Reductions in U.S. Department of Health and Human Services Regulatory Impact Analyses
This report develops an approach for valuing COVID-19 mortality and morbidity risk reductions based on the U.S. Department of Health and Human Services (HHS) Guidelines for Regulatory Impact Analysis. Valuing risk reductions associated with regulations or other policies that address the novel coronavirus disease 2019 (COVID-19) presents major challenges.
Environmental Scan
State Residential Treatment for Behavioral Health Conditions: Regulation and Policy Environmental Scan
The objective of this environmental scan is to summarize the peer-reviewed and grey literature on oversight of residential care for mental health and substance use care in the United States, excluding inpatient hospital care.
Compendium of Residential Care and Assisted Living Regulations and Policy: 2015 Edition - Delaware Profile
The purpose of this Compendium is to summarize and compare states’ residential care setting regulations. This is the Delaware state profile. A list of URLs for the full report and other state profiles can be found at the end of this paper.
Compendium of Residential Care and Assisted Living Regulations and Policy: 2015 Edition - Pennsylvania Profile
The purpose of this Compendium is to summarize and compare states’ residential care setting regulations. This is the Pennsylvania state profile. A list of URLs for the full report and other state profiles can be found at the end of this paper.